Followers | 798 |
Posts | 40041 |
Boards Moderated | 10 |
Alias Born | 06/20/2009 |
Wednesday, July 26, 2023 12:38:57 PM
Therapeutic Solutions International Approved by Amazon to sell its highly regarded immune supplement QuadraMune™ along with other brands.
PR NewswireFri, Feb. 26, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™
PR NewswireThu, Feb. 25, 2021
Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells
PR NewswireMon, Feb. 22, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction
PR NewswireThu, Feb. 18, 2021
Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board
PR NewswireTue, Feb. 16, 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
PR NewswireWed, Feb. 10, 2021
Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer
PR NewswireMon, Feb. 08, 2021
Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC
PR NewswireThu, Feb. 04, 2021
Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma
PR NewswireMon, Feb. 01, 2021
Therapeutic Solutions International Reports Enhancement of StemVacs Immune Stimulating Activity Using Neuromodulatory Compound Homotaurine
PR NewswireTue, Jan. 26, 2021
Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models
PR NewswireMon, Jan. 25, 2021
Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy
PR NewswireTue, Jan. 19, 2021
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences
PR NewswireWed, Jan. 13, 2021
Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity
PR NewswireTue, Jan. 05, 2021
Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company
PR NewswireThu, Dec. 31, 2020
Therapeutic Solutions International Reports QuadraMune™ Increases T Cell Immunity in Animal Studies
PR NewswireWed, Dec. 30, 2020
Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction
PR NewswireMon, Dec. 21, 2020
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell
PR NewswireThu, Dec. 17, 2020
Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention
PR NewswireWed, Dec. 16, 2020
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder
PR NewswireWed, Dec. 09, 2020
Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction
PR NewswireWed, Dec. 02, 2020
Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data
PR NewswireTue, Dec. 01, 2020
-----------------------------------------------------------------------------------------------------------------
below is just a brief snapshot & gets more interesting when dates of PRs & spike periods
Date Close/Last Volume Open High Low
12/01/2020 $0.0058 9,881,305 $0.0053 $0.0063 $0.005
02/17/2021 $0.127 14,819,300 $0.1365 $0.1399 $0.105
02/16/2021 $0.134 13,580,110 $0.1365 $0.15 $0.1212
02/12/2021 $0.136 21,123,780 $0.15 $0.16 $0.1016
02/11/2021 $0.15 23,450,170 $0.1375 $0.165 $0.1338
02/10/2021 $0.129 40,230,140 $0.1467 $0.17 $0.0855
02/09/2021 $0.133 47,110,050 $0.1035 $0.1729 $0.103
Recent TSOI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 05:18:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/02/2024 05:18:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:44:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:44:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 06:14:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:42:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 07:38:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:44:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:39:55 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM